| Augustin J Delago, MD | |
|
7 Southwoods Blvd, Capital Cardiology Associates, Pc, Albany, NY 12211-2526 | |
| (518) 292-6000 | |
| (518) 292-6050 |
| Full Name | Augustin J Delago |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 37 Years |
| Location | 7 Southwoods Blvd, Albany, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114911633 | NPI | - | NPPES |
| 01246744 | Medicaid | NY | |
| 1007649 | Medicaid | VT | |
| 2012260 | Medicaid | MA | |
| 060067416 | Other | NY | RR MEDICARE |
| P00011464 | Other | MA | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 183643 (New York) | Primary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 183643 (New York) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Albany Medical Center Hospital | Albany, NY | Hospital |
| St Peter's Hospital | Albany, NY | Hospital |
| Glens Falls Hospital | Glens falls, NY | Hospital |
| Samaritan Hospital | Troy, NY | Hospital |
| Saratoga Hospital | Saratoga springs, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capital Physician Associates Pllc | 1254228240 | 62 |
News Archive
Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
The genomic analysis technologies enable the study of genetic factors related to numerous diseases. In few areas this researches brought such a big and useful volume of information as in the case of melanoma.
Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.
› Verified 2 days ago
| Entity Name | Capital Physician Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518952332 PECOS PAC ID: 1254228240 Enrollment ID: O20040303000953 |
News Archive
Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
The genomic analysis technologies enable the study of genetic factors related to numerous diseases. In few areas this researches brought such a big and useful volume of information as in the case of melanoma.
Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.
› Verified 2 days ago
| Entity Name | Capital Physician Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Intensive Cardiac Rehabilitation |
| Entity Identifiers | NPI Number: 1518952332 PECOS PAC ID: 1254228240 Enrollment ID: O20220512001887 |
News Archive
Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
The genomic analysis technologies enable the study of genetic factors related to numerous diseases. In few areas this researches brought such a big and useful volume of information as in the case of melanoma.
Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Augustin J Delago, MD 7 Southwoods Blvd, Capital Cardiology Associates, Pc, Albany, NY 12211-2526 Ph: (518) 292-6000 | Augustin J Delago, MD 7 Southwoods Blvd, Capital Cardiology Associates, Pc, Albany, NY 12211-2526 Ph: (518) 292-6000 |
News Archive
Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
The genomic analysis technologies enable the study of genetic factors related to numerous diseases. In few areas this researches brought such a big and useful volume of information as in the case of melanoma.
Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.
› Verified 2 days ago
Arunima Rajbhandary, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, Albany, NY 12208 Phone: 518-525-1550 | |
Dr. Rahul Ravilla, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 43 New Scotland Ave Ste 7, Albany, NY 12208 Phone: 518-262-6696 Fax: 518-262-2624 | |
Emmanuelle Cordero Torres, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave Dept Of Nephrology, Albany Medical Center, Albany, NY 12208 Phone: 518-262-5377 | |
Nancy Shrestha, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 5 Palisades Dr Ste 200, Albany, NY 12205 Phone: 518-471-3636 Fax: 518-471-3668 | |
Stephen Hillinger, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 400 Patroon Creek Blvd, Suite 1, Albany, NY 12206 Phone: 518-489-0044 Fax: 518-489-3591 | |
Louis H Gold, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5 Palisades Dr, Ste100, Albany, NY 12205 Phone: 518-438-4496 | |
Sean Joseph Sheehan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1375 Washington Ave, Suite 101, Albany, NY 12206 Phone: 518-438-4483 Fax: 518-482-4201 |